Tomoya Muto Selected Research

Tomoya Muto Research Topics

Disease

6	Neoplasms (Cancer) 01/2022 - 01/2015
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2021 - 06/2014
4	Leukemia 01/2022 - 02/2012
4	POEMS Syndrome (Syndrome, POEMS) 01/2021 - 04/2016
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2021 - 07/2015
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 12/2021 - 01/2015
2	Hemorrhage 01/2021 - 01/2015
2	Multiple Myeloma 01/2021 - 01/2015
2	Infections 01/2018 - 01/2017
1	Myeloid Leukemia (Leukemia, Myelocytic) 01/2022
1	Inflammation (Inflammations) 01/2020
1	Eosinophilia 12/2019
1	BCR-ABL Negative Atypical Chronic Myeloid Leukemia (Leukemia, Myeloid, Philadelphia Negative) 12/2019
1	Lymphoma (Lymphomas) 10/2018
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 04/2018
1	Radiculopathy (Radiculopathy, Cervical) 01/2017
1	Meningitis 01/2017
1	Myelitis 01/2017
1	Alzheimer Disease (Alzheimer's Disease) 12/2016
1	Atherosclerosis 12/2016
1	Acute Promyelocytic Leukemia 01/2016
1	Hodgkin Disease (Hodgkin's Disease) 01/2016
1	Cytokine Release Syndrome 01/2016
1	Stomatitis 01/2016
1	Residual Neoplasm 07/2015
1	Acute Lung Injury 01/2015
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2015
1	Aplastic Anemia (Anemia, Hypoplastic) 01/2015
1	Pathologic Complete Response 01/2015
1	Intestinal Pseudo-Obstruction (Intestinal Pseudoobstruction) 02/2012
1	Hypertension (High Blood Pressure) 02/2012
1	Muscle Weakness 02/2012
1	Posterior Leukoencephalopathy Syndrome 02/2012
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 02/2012

Drug/Important Bio-Agent (IBA)

2	TNF Receptor-Associated Factor 6 (TRAF6)IBA 01/2022 - 01/2018
2	CytokinesIBA 01/2018 - 04/2016
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2017 - 01/2015
2	Biomarkers (Surrogate Marker)IBA 12/2016 - 01/2015
2	Polycomb Repressive Complex 2IBA 09/2015 - 06/2014
1	Methotrexate (Mexate)FDA LinkGeneric 12/2021
1	Busulfan (Busulfex)FDA Link 12/2021
1	PTC596IBA 01/2021
1	Proteasome InhibitorsIBA 01/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2020
1	Imatinib Mesylate (Gleevec)FDA Link 12/2019
1	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 12/2019
1	Thrombopoietin ReceptorsIBA 04/2018
1	SteroidsIBA 04/2018
1	Inosine Triphosphate (ITP)IBA 04/2018
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 02/2017
1	Acyclovir (Aciclovir)FDA LinkGeneric 01/2017
1	Foscarnet FDA LinkGeneric 01/2017
1	Membrane Proteins (Integral Membrane Proteins)IBA 12/2016
1	DNA (Deoxyribonucleic Acid)IBA 11/2016
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2016
1	Proteins (Proteins, Gene)FDA Link 04/2016
1	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 04/2016
1	HLA-B51 AntigenIBA 01/2016
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2016
1	Lysine (L-Lysine)FDA Link 07/2015
1	thymoglobulin FDA Link 01/2015
1	Rituximab (Mabthera)FDA Link 01/2015
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2015
1	Bortezomib (Velcade)FDA Link 01/2015
1	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2015
1	TetraspaninsIBA 04/2014

Therapy/Procedure

5	Stem Cell Transplantation 01/2021 - 01/2015
3	Transplantation 01/2021 - 01/2016
2	Hematopoietic Stem Cell Transplantation 01/2017 - 07/2015
2	Drug Therapy (Chemotherapy) 07/2015 - 02/2012
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2021
1	Radiotherapy 10/2018
1	Hematopoietic Stem Cell Mobilization 04/2016
1	Therapeutics 07/2015
1	Aftercare (After-Treatment) 01/2015
1	Remission Induction 02/2012